Development and validation of a RP-HPLC method for assay of atorvastatin and its application in dissolution studies on thermosensitive hydrogel-based nanocrystals

Tropical Journal of Pharmaceutical Research

Volumn 13, Issue 10, 2014, Pages 1681-1687

  Kurakula, Mallesh ^a   Sobahi, Tariq R ^a   El Helw, A ^a   Abdelaal, Magdy Y ^a,b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

Anticholestermic; Atorvastatin; Dissolution studies; Hydrogel; Nanocrystal; Thermosensitive

Indexed keywords

ATORVASTATIN; HYDROGEL BASED NANOCRYSTAL; NANOCRYSTAL; UNCLASSIFIED DRUG;

ANTENNA; ARTICLE; CLINICAL EVALUATION; DRUG DETERMINATION; DRUG FORMULATION; DRUG RESPONSE; DRUG RETENTION; DRUG SOLUBILITY; DRUG SPECIFICITY; HEAT SENSITIVITY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LINEARITY; MEASUREMENT ACCURACY; MEASUREMENT REPEATABILITY; PHARMACOLOGICAL PARAMETERS; REGRESSION ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ROBUSTNESS; RUGGEDNESS; VALIDATION PROCESS;

EID: 84908373774     PISSN: 15965996     EISSN: 15969827     Source Type: Journal    
DOI: 10.4314/tjpr.v13i10.16     Document Type: Article

References (21)

1. Acton QA. Antihyperlipidemic agents: Advances in research and application. Scholarly Editions, 2012.
2. Rundek T, Naini A, Sacco R, Coates K, Dimauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch. Neurol. 2004; 61: 889-892.
3. Kawamoto S, Kawamura T, Miyazaki Y, Hosoya T. Effects of atorvastatin on hyperlipidemia in kidney disease patients. Nihon Jinzo Gakkai Shi. 2007; 49: 41-48.
4. Conde K, Vergara-Jimenez MBR, Newton RS, Fernandez ML. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig. J. Lipid Res. 1996; 37: 2372-2382.
5. Posvar EL, Radulovic LL Jr, Cilla, DD. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J. Clin. Pharmacol. 1996; 36: 728-731.
6. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 2003; 42: 1141-1160.
7. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am. J. Cardio. 2005; 96: 44-49.
8. Cilla DD Jr, Whitfield LR, Gibson DM, Sedman AJ, Posvar EL. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin. Pharmacol. Ther. 1996; 60: 687-695.
9. Miryala V, Kurakula M. Self-nano emulsifying drug delivery systems (SNEDDS) for oral delivery of atorvastatin-formulation and bioavailability studies. J. Drug Deliv. Therap. 2013; 3: 131-142.
10. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur. J. Pharm. Biopharm. 2006; 62: 3-16.
11. Lin Z, Gao W, Hu H, Ma K, He B, Dai W, Wang X, Wang J, Zhang X, Zhang Q. Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity. J. Control. Release. 2014; 174: 161-170.
12. Ghanty S, Sadhukhan N, Mondal A. Development and validation of a UV-spectrophotometric method for quantification of atorvastatin in tablets. J. Pharma. Sci. Tech. 2012; 2: 34-40.
13. Stanisz B, Kania L. Validation of HPLC method for determination of atorvastatin tablets and for monitoring stability in solid phase. Acta Pol. Pharm. 2006; 63: 471-476.
14. Novakova L, Satinsky D, Solich P. HPLC methods for the determination of simvastatin and atorvastatin. Trends Anal. Chem. 2008; 27: 352-367.
15. Manzoor A, Manohara YN, Ravi MC. RP-HPLC method development and validation for simultaneous estimation of atorvastatin calcium and amlodipine besylate. Int. J. Chem. Tech. Res. 2012; 4: 337-345.
16. Gupta KR, Wadodkar AR, Wadodkar SG. Validated Reverse Phase HPLC method for simultaneous estimation of atorvastatin and Atenolol in tablets. Pharm. Lett. 2011; 3: 393-403.
17. Mustafa G, Azeem A, Ahmad FJ, Khan ZI, Shakeel F, Talegaonkar S. Stability-indicating RP-HPLC method for analysis of atorvastatin in bulk drug, marketed tablet and nanoemulsion formulation. J. Chil. Chem. Soc. 2010; 55: 184-188.
18. Kurakula M, Mohd AB, Samhuidrom Rao P, Diwan PV. Estimation of prednisolone in proliposomal formulation using RP -HPLC method. Int. J. Res. Pharm. Biomed. Sci. 2011; 2: 663-1669.
19. Kurakula M, Mohd AB, Rao PA, Diwan PV. Estimation of piroxicam in proliposomal formulation using RP-HPLC method. Int. J. Chem. Anal. Sci. 2011; 2: 1193-1196.
20. International Conference on Harmonization (ICH) 2003. ICH Harmonized Tripartite guideline. Validation of Analytical Procedures: Text and Methodology Q2 (R1) Current Step 4 version. Parent Guideline dated 27 October 1994. (Complementary Guideline on Methodology dated 6 November 1996; incorporated in November 2005).
21. The United States Pharmacopeia and National Formulary USP 34-NF 29; The United States Pharmacopeial Convention, Inc.: Rockville, MD, 2011.